196 related articles for article (PubMed ID: 32506123)
1. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.
Grossman SA; Romo CG; Rudek MA; Supko J; Fisher J; Nabors LB; Wen PY; Peereboom DM; Ellingson BM; Elmquist W; Barker FG; Kamson D; Sarkaria JN; Timmer W; Bindra RS; Ye X
Neuro Oncol; 2020 Oct; 22(10):1422-1424. PubMed ID: 32506123
[No Abstract] [Full Text] [Related]
2. Trends driving clinical trials into large clinical care settings.
Getz K
Nat Rev Drug Discov; 2018 Oct; 17(10):703-704. PubMed ID: 30026528
[No Abstract] [Full Text] [Related]
3. Effects of temozolomide in malignant brain tumours.
Osoba D
Lancet; 2000 Jul; 356(9226):342. PubMed ID: 11071219
[No Abstract] [Full Text] [Related]
4. Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Sampson JH; Archer G; Pedain C; Wembacher-Schröder E; Westphal M; Kunwar S; Vogelbaum MA; Coan A; Herndon JE; Raghavan R; Brady ML; Reardon DA; Friedman AH; Friedman HS; Rodríguez-Ponce MI; Chang SM; Mittermeyer S; Croteau D; Puri RK;
J Neurosurg; 2010 Aug; 113(2):301-9. PubMed ID: 20020841
[TBL] [Abstract][Full Text] [Related]
5. What have we learnt from previous phase II trials to help in the management of childhood brain tumours?
Chastagner P; Bouffet E; Grill J; Kalifa C
Eur J Cancer; 2001 Nov; 37(16):1981-93. PubMed ID: 11597375
[TBL] [Abstract][Full Text] [Related]
6. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
8. Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Olivi A; Brem H
Recent Results Cancer Res; 1994; 135():149-54. PubMed ID: 8047689
[No Abstract] [Full Text] [Related]
9. Highlighting the need for reliable clinical trials in glioblastoma.
Mandel JJ; Youssef M; Ludmir E; Yust-Katz S; Patel AJ; De Groot JF
Expert Rev Anticancer Ther; 2018 Oct; 18(10):1031-1040. PubMed ID: 29973092
[TBL] [Abstract][Full Text] [Related]
10. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
van Bussel MTJ; Beijnen JH; Brandsma D
BMC Cancer; 2019 May; 19(1):519. PubMed ID: 31146733
[TBL] [Abstract][Full Text] [Related]
11. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
12. A decision theoretical modeling for Phase III investments and drug licensing.
Miller F; Burman CF
J Biopharm Stat; 2018; 28(4):698-721. PubMed ID: 28920757
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
14. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
[TBL] [Abstract][Full Text] [Related]
15. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
Edelman MJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869
[No Abstract] [Full Text] [Related]
16. Improved drug-delivery nanoparticles penetrate brain.
Coaker H
Future Med Chem; 2012 Nov; 4(17):2135. PubMed ID: 23190099
[No Abstract] [Full Text] [Related]
17. Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
Brower JV; Robins HI
Expert Opin Pharmacother; 2016; 17(7):1013-21. PubMed ID: 26967582
[TBL] [Abstract][Full Text] [Related]
18. Genomics drugs in clinical trials.
Hall J; Dennler P; Haller S; Pratsinis A; Säuberli K; Towbin H; Walther K; Woytschak J
Nat Rev Drug Discov; 2010 Dec; 9(12):988. PubMed ID: 21119735
[No Abstract] [Full Text] [Related]
19. [Drug clinics. Clinical drug trials: the importance and role of the general practitioner].
Scheen AJ
Rev Med Liege; 1998 Jan; 53(1):17-20. PubMed ID: 9555177
[TBL] [Abstract][Full Text] [Related]
20. Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
Chamberlain MC
Neuro Oncol; 2011 May; 13(5):558-9; author reply 561-2. PubMed ID: 21558078
[No Abstract] [Full Text] [Related]
[Next] [New Search]
